About aTyr Pharma Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.atyrpharma.com/
Frequently Asked Questions
What is the 52-week range for ATYR?
The 52-week high is $1.12 and the 52-week low is $0.272.
What is the P/E ratio for ATYR?
The P/E ratio data is currently unavailable.
What is the dividend yield for ATYR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -99.62%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -13549.47%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.14.
Analyst Recommendation Trends
Wall Street analyst consensus for ATYR over the last few months:
Latest ATYR News
Discover the most active stocks in Thursday's session.
Stay updated with the latest market activity on Thursday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
aTyr Pharma Inc. (NASDAQ:ATYR) secured a formal agreement with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 study protocol for its lead therapeutic candidate, efzofitimod. Following this regulatory alignment, the company prepares to initiate study-related activities across the U.S. and Europe in the fourth quarter of 2026. Phase 3 Trial Design And Endpoints The upcoming Phase 3 clinical trial aims to assess both the overall safety and effectiveness of efzofitimod in individu
aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis
aTyr Pharma plans to begin study-related activities in the fourth quarter of 2026 after reaching FDA alignment on a global Phase 3 efzofitimod trial, although further development will require additional capital. Key Investor TakeawaysaTyr Pharma (NASDAQ:ATYR) has reached alignment with the FDA on the protocol for a Phase 3 efzofitimod study in pulmonary sarcoidosis.
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint. Company expects to initiate study-related activities in the fourth quarter of 2026. SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, toda
aTyr Pharma Reaches FDA Alignment On Protocol For A Phase 3 Study Of Its Lead Therapeutic Candidate Efzofitimod In Patients With Chronic, Symptomatic Pulmonary Sarcoidosis With Restrictive Lung Disease; Expects To Initiate Study-Related Activities In Q4 2026
The planned Phase 3 trial will be a global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of efzofitimod in patients with moderate to severe pulmonary sarcoidosis. The 54-week
Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight
Recently published Sarcoidosis Market Insights report includes a comprehensive understanding of current treatment practices, sarcoidosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-10-01 | Yaras Brandon | +410,000 | - | - |
| 2026-05-27 | SCHIMMEL PAUL | +100,000 | $0.4963 | $49,630 |
| 2026-05-11 | Lucas Svetlana | +50,000 | - | - |
| 2026-05-11 | Gross Jane A | +50,000 | - | - |
| 2026-05-11 | BENEVICH ERIC | +50,000 | - | - |
| 2026-05-11 | Zaknoen Sara | +50,000 | - | - |
| 2026-05-11 | Coughlin Timothy | +50,000 | - | - |
| 2026-05-11 | SCHIMMEL PAUL | +50,000 | - | - |
| 2026-02-04 | Shukla Sanjay | -3,745 | $0.976 | $3,655 |
| 2026-02-04 | DENYES NANCY | -1,118 | $0.9761 | $1,091 |
| 2026-02-04 | Broadfoot Jill Marie | -1,558 | $0.976 | $1,521 |
| 2026-02-03 | Shukla Sanjay | -10,375 | - | - |
| 2026-02-03 | Shukla Sanjay | +10,375 | - | - |
| 2026-02-03 | DENYES NANCY | -2,687 | - | - |
| 2026-02-03 | DENYES NANCY | +2,687 | - | - |
| 2026-02-03 | Broadfoot Jill Marie | -3,750 | - | - |
| 2026-02-03 | Broadfoot Jill Marie | +3,750 | - | - |
| 2026-01-09 | Shukla Sanjay | +1,500,000 | - | - |
| 2026-01-09 | DENYES NANCY | +412,500 | - | - |
| 2026-01-09 | Broadfoot Jill Marie | +412,500 | - | - |
| 2025-10-09 | SCHIMMEL PAUL | +317,999 | $0.9414 | $299,364 |
| 2025-10-08 | SCHIMMEL PAUL | +682,001 | $0.898 | $612,437 |